Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Amrutanjan Health CareBOM:590006 -0.70%71 ROA % is 3.43% as of Jun. 2026, which is 73% below its 10-year median of 12.84. GuruFocus rates BOM:590006 with a GF Score™ of 71/100 and a GF Value™ of ₹827.69 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Amrutanjan Health Care ranks better than 87.6% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Amrutanjan Health Care's annualizedNet Income for the quarter that ended in Jun. 2026 was ₹175 Mil.
Amrutanjan Health Care's average Total Assets over the quarter that ended in Jun. 2026 was ₹5,089 Mil. Therefore, Amrutanjan Health Care's annualized ROA % for the quarter that ended in Jun. 2026 was 3.43%.
The historical rank and industry rank for Amrutanjan Health Care's ROA % or its related term are showing as below:
BOM:590006'
s ROA % Range Over the Past 10 Years
Min: 11.19 Med: 12.84 Max: 25.52
Current: 11.88
During the past 13 years, Amrutanjan Health Care's highest ROA % was 25.52%. The lowest was 11.19%. And the median was 12.84%.
BOM:590006's ROA % is ranked better than 87.6% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 2.485
vs BOM:590006: 11.88
Amrutanjan Health Care (BOM:590006) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Jun. 2026) net income data. The Revenue data used here is four times the quarterly (Jun. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Amrutanjan Health Care's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amrutanjan Health Care ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amrutanjan Health Care's ROA % distribution charts can be found below:
* The bar in red indicates where Amrutanjan Health Care's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Amrutanjan Health Care (BOM:590006) has a ROA % of 3.43% as of Jun. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Amrutanjan Health Care and its competitors. This is 73% below median its historical median of 12.84. Over the past decade, Amrutanjan Health Care's ROA % has ranged from 11.19 to 25.52. According to the industry distribution chart, Amrutanjan Health Care ranks #125 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 12.4%.
Is Amrutanjan Health Care's ROA % too high?
Amrutanjan Health Care's current ROA % of 3.43% is 73% below median its 10-year median of 12.84. Over the past 10 years, this metric has ranged from a low of 11.19 to a high of 25.52. The Drug Manufacturers industry median ROA % is 2.49. Amrutanjan Health Care's value of 3.43% is 38% above this industry median. Based on the distribution chart, Amrutanjan Health Care ranks #125 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Amrutanjan Health Care has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amrutanjan Health Care's ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Amrutanjan Health Care ranks #125 out of 1008 companies for ROA %. This places Amrutanjan Health Care in the top 12% of its industry — outperforming the majority of peers. The industry median ROA % is 2.49. Amrutanjan Health Care's value of 3.43% is 38% above this benchmark. Historically, Amrutanjan Health Care's own ROA % has ranged from 11.19 to 25.52 over the past decade. While the company's 10-year median is 12.84 vs. the industry median of 2.49, Amrutanjan Health Care has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.49, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amrutanjan Health Care's current ROA % of 3.43% is 38% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Amrutanjan Health Care and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amrutanjan Health Care's current ROA % is 3.43%, which is 73% below median its own 10-year median of 12.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amrutanjan Health Care stock overvalued right now?
Based on GuruFocus' analysis, Amrutanjan Health Care (BOM:590006) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹827.69, compared to a current price of ₹490.35 — trading 40.8% below its estimated fair value. The current ROA % is 3.43%, which is 73% below median its 10-year median of 12.84 and 38% above the Drug Manufacturers industry median of 2.49. Amrutanjan Health Care's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Amrutanjan Health Care (BOM:590006), the current ROA % is 3.43% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amrutanjan Health Care (BOM:590006) Overvalued in 2026?
Based on GuruFocus' analysis, Amrutanjan Health Care stock appears to be undervalued.
The current stock price of ₹490.35 is trading 40.8% below its estimated GF Value™ of ₹827.69.
GuruFocus considers Amrutanjan Health Care to be Significantly Undervalued.
Key valuation signals for BOM:590006:
ROA %: 3.43% (73% below median its 10-year median of 12.84)
GF Value™: ₹827.69 vs. price of ₹490.35 (40.8% below fair value)
Industry Position: 38% above the Drug Manufacturers median (#125 of 1008)
No single metric tells the full story. See the BOM:590006 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amrutanjan Health Care Ltd manufactures Ayurvedic and allopathic products. The company operates through the following segments: OTC Products, Beverages, and Others. The majority of the revenue is generated from its OTC segment which is engaged in the manufacturing products of pain management, congestion management, and hygiene. Its beverage segment includes manufacturing fruit juices and oral rehydration drinks. Some of its products include Roll-on, Spray, Balm, Cough Syrup, Sanitary napkins, and inhalers. Geographically, it generates the majority of the revenue from India.
71GF Score
Get the complete analysis for BOM:590006
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:590006 has been successfully added to your 
